Bayer HealthCare upbeat on Asia-Pacific prospects after solid 2011
This article was originally published in Scrip
Bayer HealthCare's Asia-Pacific expansion is being driven by growth for new and existing products across both emerging and established markets, which pushed total sales in the region up by a currency-adjusted 9% to €3.66 billion in calendar 2011.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.